Pilot randomised controlled trial of augmented depression therapy

Improving depression treatment outcomes by better repairing positivity deficits: A Feasibility pilot randomised controlled trial evaluation of an Augmented Depression Therapy targeting wellbeing (ADepT)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN85278228

Enrollment

Registered

2017-03-27

Start date

2017-03-29

Completion date

Unknown

Last updated

2025-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Specialty: Mental Health, Primary sub-specialty: Depression

Interventions

Participants are randomly allocated to either receiving augmented depression therapy or cognitive behaviour therapy. Augmented Depression Therapy (ADepT) consists of up to 15 weekly core therapy sess

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Aged over 18 or over 2. Suffering from a current major depressive episode (MDE) assessed by structured clinical interview for diagnosis (SCID-I) 3. Have a Patient Health Questionnaire (PHQ-9) depression score =>10 4. Present with significant anhedonic symptoms (PHQ-9 item 1 score =>2)

Exclusion criteria

Exclusion criteria: 1. Depression is not the primary presenting problem 2. Alcohol or drug dependent 3. Acutely suicidal or self-harming 4. Cognitively impaired 5. Have bipolar disorder or psychosis/psychotic symptoms ascertained at baseline research interviews 6. Currently receiving another psychological therapy

Design outcomes

Primary

Measure	Time frame
1. Severity of depression and anxiety symptoms are measured using the 9 item Patient Health Questionnaire (PHQ-9; Kroenke et al., 2001) and the 7 item version of the Generalized Anxiety Disorder questionnaire (GAD-7; Spitzer et al., 2006) at baseline, six, 12 and 18 months 2. Wellbeing outcomes are measured using the 14 item version of the Warwick-Edinburgh Mental Wellbeing Scale (WEMWBS; Clark et al., 2003) at baseline, six, 12 and 18 months 3. Cost of therapies are measured using records from therapists (including training, preparation, supervision, session, and travel time) using standard micro-costing (bottom-up) approaches at baseline, six, 12 and 18 months 4. Participants views and experiences are assessed with feedback booklets at the end of treatment, with a subset of respondents being invited to take part in interviews between the end of treatment and 12 month follow-up	—

Measure

Time frame

1. Severity of depression and anxiety symptoms are measured using the 9 item Patient Health Questionnaire (PHQ-9; Kroenke et al., 2001) and the 7 item version of the Generalized Anxiety Disorder questionnaire (GAD-7; Spitzer et al., 2006) at baseline, six, 12 and 18 months 2. Wellbeing outcomes are measured using the 14 item version of the Warwick-Edinburgh Mental Wellbeing Scale (WEMWBS; Clark et al., 2003) at baseline, six, 12 and 18 months 3. Cost of therapies are measured using records from therapists (including training, preparation, supervision, session, and travel time) using standard micro-costing (bottom-up) approaches at baseline, six, 12 and 18 months 4. Participants views and experiences are assessed with feedback booklets at the end of treatment, with a subset of respondents being invited to take part in interviews between the end of treatment and 12 month follow-up

—

Secondary

Measure	Time frame
1. Impact of ADepT versus CBT are measured using patient self-report, laboratory experimental and experience sampling data at baseline and six months 2. Health economic analyses are measured using Adult Service Use Schedule (AD-SUS), the Investigating Choice Experiments Capability Measure for Adults (ICECAP-A), the EuroQol Five Dimensions Questionnaire (EQ-5D-5L), and the Absenteeism and Presenteeism items of the World Health Organization Health and Performance Questionnaire (HPQ) at baseline, six, twelve and eighteen months	—

Measure

Time frame

1. Impact of ADepT versus CBT are measured using patient self-report, laboratory experimental and experience sampling data at baseline and six months 2. Health economic analyses are measured using Adult Service Use Schedule (AD-SUS), the Investigating Choice Experiments Capability Measure for Adults (ICECAP-A), the EuroQol Five Dimensions Questionnaire (EQ-5D-5L), and the Absenteeism and Presenteeism items of the World Health Organization Health and Performance Questionnaire (HPQ) at baseline, six, twelve and eighteen months

—

Countries

England, United Kingdom

Contacts

Public ContactBarney Dunn

b.d.dunn@exeter.ac.uk+44 (0)1392 726449

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 10, 2026